Steve K. DobersteinPhD
Steve Doberstein joined Nektar in January 2010 as Senior Vice President and Chief Scientific Officer to lead discovery research at Nektar. Dr. Doberstein brings over 20 years of experience in biotechnology research and development to the company. Prior to joining Nektar, Dr. Doberstein served as Vice President of Research at XOMA, Five Prime Therapeutics, and Xencor, and held a variety of senior positions at Exelixis. His experience spans small molecule, protein therapeutics, and monoclonal antibody discovery and development in therapeutic areas including oncology, neuroscience, inflammation, immunology, and metabolic diseases. Dr. Doberstein also serves as the Chairman of the Board of Nektar India.
Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine where he studied in the laboratory of Dr. Thomas Pollard, and completed his postdoctoral work in Dr. Corey Goodman's laboratory at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.